Latest Posts:

Sorry, no posts matched your criteria.

Follow Us:

Back To Top

JOIN OUR EFFORTS TO

ENABLE FULL IDENTIFICATION, FULL CLEARANCE

through venture.

Relying on surface, or even internal markers will always be a flawed strategy because they are never universal, constantly changing, and are often completely hidden during intermediate states, creating an advantage for the genetic profile not caught by the initial therapeutic dose.

One approach that has fallen in and out of favour over the years, is to use viruses which can selectively infect cancerous cells due to specific genetic or metabolic phenotypes, such as unregulated replication. This can then be used to lyse cancer cells, display a marker to the immune system, produce cytokines or prodrug convertase. The problem with this approach is that the virus are highly unlikely to make it into all of the cancerous cells because it is quickly spotted by the immune system and destroyed. Either pre-existing or adaptive immunity presents a problem, the immune system can destroy the virus quicker than it can destroy the tumour. The result is again being impressive initial results followed later by what is often even more aggressive recurrence.

approaches we’re considering

Our starting point to explore this space is to ask how we can create a more effective balance between, on the one hand, evading the immune system and on the other hand, getting into every cancerous cell whilst pervading the tumour microenvironment. Next, once we have achieved this selective penetration, how do we drive a therapeutic regime that does not allow resistance to emerge?

our offer

Your role will start as a Founder within DSV under our unique framework for venture creation. It’s a full time role working across market analysis, science and customer development together with the DSV team before incorporating your own start-up within 6 months (give or take a couple of months) with pre-seed investment from DSV.

We already have a number of exciting projects being developed in this space and expect to make first investments into newly formed startups and founding teams by the end of the year. 

Our partnership with Cancer Research UK means that your work will also be supported by the world’s largest independent funder of cancer research. Further information about the DSV-CRUK partnership here.

No prior idea or IP required.

who should apply

Someone coming from the oncolytic virus field with experience in either measles virus, vaccinia virus, adenovirus, reovirus, parvovirus, picornavirus, herpesvirus etc. and having practical knowledge of modification of the viral envelope or capsids or design of synthetic alternatives for immune evasion / stealth strategies.

Alternatively, we are interested in someone that is familiar with exosomes, targeting and loading. Additional experience in evaluating immunogenic cell death, cytokine expression and immune stimulation is also desired.

The preferred candidate will originate from one of the key companies or academic groups in the space and have a deep understanding of one area and a good grasp of other relevant fields. Most importantly, the candidates should have an enthusiasm for innovation, be entrepreneurial and adaptable.

Relying on surface, or even internal markers will always be a flawed strategy because they are never universal, constantly changing, and are often completely hidden during intermediate states, creating an advantage for the genetic profile not caught by the initial therapeutic dose.

One approach that has fallen in and out of favour over the years, is to use viruses which can selectively infect cancerous cells due to specific genetic or metabolic phenotypes, such as unregulated replication. This can then be used to lyse cancer cells, display a marker to the immune system, produce cytokines or prodrug convertase. The problem with this approach is that the virus are highly unlikely to make it into all of the cancerous cells because it is quickly spotted by the immune system and destroyed. Either pre-existing or adaptive immunity presents a problem, the immune system can destroy the virus quicker than it can destroy the tumour. The result is again being impressive initial results followed later by what is often even more aggressive recurrence.

approaches we’re considering

Our starting point to explore this space is to ask how we can create a more effective balance between, on the one hand, evading the immune system and on the other hand, getting into every cancerous cell whilst pervading the tumour microenvironment. Next, once we have achieved this selective penetration, how do we drive a therapeutic regime that does not allow resistance to emerge?

our offer

Your role will start as a Founder within DSV under our unique framework for venture creation. It’s a full time role working across market analysis, science and customer development together with the DSV team before incorporating your own start-up within 6 months (give or take a couple of months) with pre-seed investment from DSV.

We already have a number of exciting projects being developed in this space and expect to make first investments into newly formed startups and founding teams by the end of the year. 

Our partnership with Cancer Research UK means that your work will also be supported by the world’s largest independent funder of cancer research. Further information about the DSV-CRUK partnership here.

No prior idea or IP required.

who should apply

Someone coming from the oncolytic virus field with experience in either measles virus, vaccinia virus, adenovirus, reovirus, parvovirus, picornavirus, herpesvirus etc. and having practical knowledge of modification of the viral envelope or capsids or design of synthetic alternatives for immune evasion / stealth strategies.

Alternatively, we are interested in someone that is familiar with exosomes, targeting and loading. Additional experience in evaluating immunogenic cell death, cytokine expression and immune stimulation is also desired.

The preferred candidate will originate from one of the key companies or academic groups in the space and have a deep understanding of one area and a good grasp of other relevant fields. Most importantly, the candidates should have an enthusiasm for innovation, be entrepreneurial and adaptable.

Interviews ongoing

Places are allocated as soon as the right fit is found.

Interviews ongoing

Places are allocated as soon as the right fit is found.

current founders

 

Chris has a background in Drug Discovery and Biotech. He’s working on educating the immune system to recognise and eliminate solid tumours through the use of oncolytic viruses or gene delivery using other vectors. To learn more about Chris’ work, you can e-mail him here.

Chris has a background in Drug Discovery and Biotech. He’s working on educating the immune system to recognise and eliminate solid tumours through the use of oncolytic viruses or gene delivery using other vectors. To learn more about Chris’ work, you can e-mail him here.